Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
  1. Homepage
  2. Equities
  3. United Kingdom
  4. London Stock Exchange
  5. GSK plc
  6. News
  7. Summary
    GSK   GB00BN7SWP63

GSK PLC

(GSK)
  Report
Delayed London Stock Exchange  -  11:35 2022-12-07 am EST
1492.40 GBX   +7.54%
12:29pGlobal Recession Jitters Offset Upward Revision Q3 Eurozone Growth as European Stocks Extend Slide
MT
12:26pLONDON MARKET CLOSE: Pharma stocks fail to lift FTSE 100 in the green
AN
09:54aTrending: GSK, Sanofi in Focus After U.S. Judge Dismisses Zantac Lawsuit
DJ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Nestle CEO: I'm not a 'mega deal' maker

09/29/2022 | 04:14am EST
Nestle CEO Schneider at Wydhof farm visit in Flaach

ZURICH (Reuters) - Food group Nestle is in no hurry to acquire companies given rich valuations and will stick to its traditionally cautious approach to deals, its chief executive told a conference on Thursday.

"I've done hundreds of deals in my life, the largest one ever was Starbucks at 7 billion so I'm not a 'mega deal' maker," Mark Schneider said in a discussion organised by Bernstein.

"I'm a strong believer in that statement by former U.S. President Obama: don't do stupid stuff. That to me in M&A is sort of the guiding light. You have to stay level-headed, down to earth, even if something looks attractive on paper it has to add up in all components," he said.

(Reporting by Silke Koltrowitz; Editing by Michael Shields)


ę Reuters 2022
Stocks mentioned in the article
ChangeLast1st jan.
GSK PLC 7.54% 1492.4 Delayed Quote.-15.56%
NESTLÉ S.A. -2.08% 109.26 Delayed Quote.-12.45%
STARBUCKS CORPORATION 0.19% 102.295 Delayed Quote.-12.73%
All news about GSK PLC
12:29pGlobal Recession Jitters Offset Upward Revision Q3 Eurozone Growth as European Stocks E..
MT
12:26pLONDON MARKET CLOSE: Pharma stocks fail to lift FTSE 100 in the gree..
AN
09:54aTrending: GSK, Sanofi in Focus After U.S. Judge Dismisses Zantac Lawsuit
DJ
09:09aSector Update: Health Care Stocks Flat To Lower Premarket Wednesday
MT
09:06aMarketScreener's World Press Review: December 7
MS
08:08aRecession Warnings Weigh on Exchange-Traded Funds, Stock Futures Premarket Wednesday
MT
07:35aGSK Says it Will Continue to Defend Itself Vigorously in Zantac Cases at State Level in..
MT
07:16aLONDON MARKET MIDDAY: Stocks slide amid risk-off mood after China d..
AN
06:58aDrugmaker shares jump as Zantac lawsuits dismissed
RE
06:32aEuropean Midday Briefing: Shares Extend Losses on Economic Worr..
DJ
More news
Analyst Recommendations on GSK PLC
More recommendations
Financials
Sales 2022 29 172 M 35 703 M 35 703 M
Net income 2022 5 302 M 6 489 M 6 489 M
Net Debt 2022 14 624 M 17 898 M 17 898 M
P/E ratio 2022 12,9x
Yield 2022 4,30%
Capitalization 60 606 M 73 791 M 74 174 M
EV / Sales 2022 2,58x
EV / Sales 2023 2,50x
Nbr of Employees 90 096
Free-Float 93,7%
Chart GSK PLC
Duration : Period :
GSK plc Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends GSK PLC
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 23
Last Close Price 1 387,80 GBX
Average target price 1 686,23 GBX
Spread / Average Target 21,5%
EPS Revisions
Managers and Directors
Emma N. Walmsley Chief Executive Officer & Executive Director
Iain James Mackay Chief Financial Officer & Executive Director
Jonathan Richard Symonds Non-Executive Chairman
Jon Ellis VP & Head-Technology Business Development
Tony Wood Chief Scientific Officer
Sector and Competitors
1st jan.Capi. (M$)
GSK PLC-15.56%68 976
JOHNSON & JOHNSON4.51%460 411
ELI LILLY AND COMPANY33.69%350 179
ABBVIE INC.20.92%289 437
NOVO NORDISK A/S21.77%285 921
PFIZER, INC.-14.09%279 038